vorinostat has been researched along with Dermatitis Medicamentosa in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma." | 9.30 | Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. ( Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB, 2019) |
| " We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate." | 7.74 | Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. ( Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W, 2008) |
| " A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma." | 5.30 | Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. ( Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB, 2019) |
| " We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate." | 3.74 | Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. ( Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W, 2008) |
| "Vorinostat was administered at the assigned dosage level (100-400 mg, three times weekly) in a standard 3 + 3 dose escalation design." | 2.90 | A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. ( Agrawal, A; Baiocchi, R; Blakaj, D; Carrau, R; Diavolitsis, V; Grecula, J; Kang, S; Kumar, B; Kumar, P; Old, MO; Ozer, E; Palettas, M; Pan, Q; Rocco, J; Savvides, P; Teknos, TN; Wei, L, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teknos, TN | 1 |
| Grecula, J | 1 |
| Agrawal, A | 1 |
| Old, MO | 1 |
| Ozer, E | 1 |
| Carrau, R | 1 |
| Kang, S | 1 |
| Rocco, J | 1 |
| Blakaj, D | 1 |
| Diavolitsis, V | 1 |
| Kumar, B | 1 |
| Kumar, P | 1 |
| Pan, Q | 1 |
| Palettas, M | 1 |
| Wei, L | 1 |
| Baiocchi, R | 1 |
| Savvides, P | 1 |
| Gordon, SW | 1 |
| McGuire, WP | 1 |
| Shafer, DA | 1 |
| Sterling, RK | 1 |
| Lee, HM | 1 |
| Matherly, SC | 1 |
| Roberts, JD | 1 |
| Bose, P | 1 |
| Tombes, MB | 1 |
| Shrader, EE | 1 |
| Ryan, AA | 1 |
| Kmieciak, M | 1 |
| Nguyen, T | 1 |
| Deng, X | 1 |
| Bandyopadhyay, D | 1 |
| Dent, P | 1 |
| Poklepovic, AS | 1 |
| Steinhoff, M | 1 |
| Beyer, M | 1 |
| Roewert-Huber, J | 1 |
| Lukowsky, A | 1 |
| Assaf, C | 1 |
| Sterry, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma[NCT01075113] | Phase 1 | 16 participants (Actual) | Interventional | 2010-08-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for vorinostat and Dermatitis Medicamentosa
| Article | Year |
|---|---|
A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
Topics: Anemia; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Drug Eruptions; Female; Head and Neck N | 2019 |
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug I | 2019 |
1 other study available for vorinostat and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fev | 2008 |